12,100 Shares in Twist Bioscience Co. (NASDAQ:TWST) Acquired by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS bought a new stake in Twist Bioscience Co. (NASDAQ:TWST) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 12,100 shares of the company’s stock, valued at approximately $562,000.

A number of other large investors also recently added to or reduced their stakes in the company. Hillsdale Investment Management Inc. lifted its position in shares of Twist Bioscience by 0.4% during the fourth quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company’s stock worth $3,625,000 after purchasing an additional 300 shares in the last quarter. American Century Companies Inc. lifted its holdings in Twist Bioscience by 63.5% during the 4th quarter. American Century Companies Inc. now owns 756,352 shares of the company’s stock worth $35,148,000 after buying an additional 293,751 shares in the last quarter. Magnetar Financial LLC purchased a new position in Twist Bioscience in the 4th quarter valued at approximately $337,000. Teacher Retirement System of Texas grew its stake in shares of Twist Bioscience by 18.9% in the fourth quarter. Teacher Retirement System of Texas now owns 17,357 shares of the company’s stock worth $807,000 after acquiring an additional 2,755 shares in the last quarter. Finally, Thrivent Financial for Lutherans increased its position in shares of Twist Bioscience by 54.6% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock worth $69,972,000 after acquiring an additional 532,040 shares during the period.

Insider Activity

In other news, CFO Adam Laponis sold 5,886 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $43.26, for a total value of $254,628.36. Following the completion of the sale, the chief financial officer now directly owns 110,096 shares in the company, valued at approximately $4,762,752.96. The trade was a 5.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert Chess sold 5,000 shares of Twist Bioscience stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $50.00, for a total transaction of $250,000.00. Following the completion of the transaction, the director now directly owns 16,641 shares of the company’s stock, valued at $832,050. This trade represents a 23.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,799 shares of company stock worth $1,593,944 over the last 90 days. Company insiders own 3.01% of the company’s stock.

Twist Bioscience Price Performance

Shares of Twist Bioscience stock opened at $38.21 on Thursday. The business’s fifty day moving average price is $44.47 and its 200 day moving average price is $45.23. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $2.28 billion, a P/E ratio of -11.30 and a beta of 2.15.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. During the same quarter in the prior year, the business earned ($0.75) earnings per share. The business’s quarterly revenue was up 24.1% compared to the same quarter last year. As a group, research analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on TWST shares. Barclays set a $58.00 price target on Twist Bioscience and gave the stock an “overweight” rating in a report on Monday, February 3rd. Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Robert W. Baird lifted their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 4th. Wolfe Research initiated coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Twist Bioscience has an average rating of “Moderate Buy” and an average target price of $54.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.